long intergenic non-protein coding RNA 2196Genealiases: []
Q-omics provides the consensus-scored LINC02196 profile across patient tissues and cancer cell-line models. LINC02196 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, LINC02196 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, LINC02196 RNA expression shows 10,944 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, HNSC, and GBM as cancer lineages where LINC02196 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02196 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02196 survival associations across molecular data types. LINC02196 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02196 RNA expression–survival associations across cancer types. High LINC02196 expression shows unfavorable associations in LIHC, UCEC, BRCA, READ, KIRP and COAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LIHC as the clearest survival context for LINC02196 RNA expression.
This table summarizes LINC02196 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02196. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02196 shows lower tumor expression in KICH and higher tumor expression in HNSC, BRCA, LUAD, LUSC and LIHC. The HNSC box plot shows higher LINC02196 RNA expression in tumor versus normal tissue (log2 FC = +0.120, t-test p = .005).
This table shows molecular features associated with LINC02196 in patient tissues and cancer cell lines. In patient samples, LINC02196 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
